FDA grants RPDD to ReviR’s RTX-117 for CMT
The designation covers CMT as a whole and is not restricted to specific subtypes.
Drug Development
ViiV Healthcare’s Tivicay PD gains FDA approval for paediatric HIV therapy
Jazz secures FDA approval for Ziihera in advanced HER2+ GEA
McKesson to acquire Precision Medicine Group for $2.25bn
Lundbeck’s asedebart receives EC orphan designation in Cushing’s syndrome
Takeda’s Orzeyful secured Japan MHLW approval for narcolepsy type 1
Gossamer Bio announces $250m in funding to advance seralutinib
WellSpan and Johns Hopkins renew partnership for advanced cancer care access
